Description
Sterile injectable, biodegradable and isotonic gel for intra-articular use.
Condronil IAL consists of a medium molecular weight hyaluronic acid (1.0 - 1.5 x 10 ⁶ Dalton), produced by Streptococcus equi bacteria, formulated at a concentration of 16 mg/ml in a physiological buffer.
Condronil IAL is characterized by viscoelastic properties, therefore it helps to normalize the viscosity of the synovial fluid present in the intra-articular cavity.
Substitute for synovial fluid in joints affected by degenerative or mechanical arthropathy, which causes pain or reduced mobility.
It acts only at the level of the joint into which it is injected without exerting any systemic action.
Sterile product.

How to use
Remove any joint effusion before injecting Condronil IAL; the same needle must be used for removal of the effusion and injection of Condronil IAL.
Remove the protective cap from the syringe, taking special care to avoid contact with the opening. Gently grasp the needle guard and fit the needle onto the Luer-lock fitting, screwing firmly until you feel a slight back pressure to ensure a watertight seal and prevent gel leakage during administration. The needle should be between 18 and 22 G in diameter.
Before injection, treat the site with a suitable disinfectant. Inject Condronil IAL using an aseptic technique. Inject only into the joint cavity.
It is recommended to carry out an initial cycle of three treatment sessions, at intervals of one week from each other, followed possibly by maintenance sessions, according to the medical prescription.

Components
Sodium hyaluronate (16 mg/ml), sodium chloride, sodium phosphate monobasic dihydrate, sodium phosphate dibasic dodecahydrate, water for injection

Warnings
Indicated for intra-articular injections only and should only be dispensed by a physician who has received specific training in the intra-articular injection technique.
Before use, check the integrity of the syringe and the expiry date.
Do not use needles other than those indicated.
The product should not be injected in the presence of an infected or severely inflamed joint. Infiltration should be avoided in case of active infections or inflammatory conditions of the skin near the site of infiltration.
Since no clinical data are available on the use of hyaluronate in children, treatment with Condronil IAL in these cases is not recommended.
It is advisable to advise the patient, after the intra-articular injection, to avoid physical activities that are demanding for the joint and to resume normal activities after a couple of days.
Condronil IAL is a single-use product, quality and sterility are guaranteed only if the syringe is sealed. Any residue must therefore be disposed of and not reused even after new sterilization.
Do not use the product if the packaging is already opened or damaged.
The syringe complete with needle must be discarded immediately after use, even if the solution has not been completely administered. After use, dispose of according to current regulations.
There are incompatibilities between sodium hyaluronate and quaternary ammonium compounds, such as benzalkonium chloride solutions. Therefore, avoid contact between Condronil IAL and these substances.
Some transient side effects may occur following the injection of Condronil IAL, such as pain, stiffness, sensation of heat, redness or swelling. These secondary manifestations can be alleviated by applying ice to the treated joint. They usually disappear after a short time. If the symptoms persist, contact a doctor. Any other unwanted side effects associated with the injection of Condronil IAL should be reported to your doctor.

Conservation
Store Condronil IAL at 2-25 °C (36-77 °F) in a dry place in the original box. Protect from light, heat and frost. Keep out of reach of children.
Validity with intact packaging: 36 months.

Format
2 ml pre-filled syringe